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 Abstract 
 Objective. To examine drug treatment in nursing home patients at the end of life, and identify predictors of palliative drug 
therapy.  Design. A historical cohort study.  Setting. Three urban nursing homes in Norway.  Subjects. All patients admitted 
from January 2008 and deceased before February 2013.  Main outcome measures. Drug prescriptions, diagnoses, and demo-
graphic data were collected from electronic patient records. Palliative end-of-life drug treatment was defi ned on the basis 
of indication, drug, and formulation.  Results. 524 patients were included, median (range) age at death 86 (19 – 104) years, 
59% women. On the day of death, 99.4% of the study population had active prescriptions; 74.2% had palliative drugs 
either alone (26.9%) or concomitantly with curative/preventive drugs (47.3%). Palliative drugs were associated with nurs-
ing home, length of stay    16 months (AOR 2.10, 95% CI 1.12 – 3.94), age (1.03, 1.005 – 1.05), and a diagnosis of cancer 
(2.12, 1.19 – 3.76). Most initiations of palliative drugs and withdrawals of curative/preventive drugs took place on the day 
of death.  Conclusion. Palliative drug therapy and drug therapy changes are common for nursing home patients on the last 
day of life. Improvements in end-of-life care in nursing homes imply addressing prognostication and earlier response to 
palliative needs. 
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more heterogeneous NH populations is lacking. 
Derived from international and Norwegian guide-
lines [6 – 8], a shorter drug list has been recommended 
for use in NHs in Norway, comprising parenteral 
morphine, benzodiazepines, anticholinergics, and 
antipsychotics [2,5]. Previous studies on EOL care 
in NHs have reported on treatment with selected 
drug groups such as opioids and pulmonary agents 
[9], and pain relief [4] without a clearly defi ned 
palliative drug treatment. 
 Pharmacological treatment for dying patients is 
thus an important aspect of EOL care in NHs, of 
which we have little knowledge. Insight into initiation 
and discontinuation of drug therapy in this phase 
may shed light on the quality of EOL care and point 
to vulnerable patient groups. Our study aimed to 
examine drug treatment in NH patients at the EOL, 
and to identify predictors of a clearly defi ned palliative 
drug therapy. 
 Introduction 
 In Norway, 47.5% of deaths occur in nursing homes 
(NHs), 32.5% in hospitals, and 14.5% at home [1]. 
About 95% of patients in long-term care will die in 
the institution [2]. NH patients are prescribed a 
wider range of medications than any other subpopu-
lation [3,4]. For the dying patient, standing drug 
treatments must be reconsidered and often discon-
tinued. The last days of life are often characterized 
by symptoms such as pain, respiratory distress, and 
anxiety, as well as inability to take oral medications 
[5]. These symptoms may be palliated by parenterally 
administered drugs [6]. 
 Whereas palliative literature has a main focus on 
specialized care for patients with cancer in hospice 
and hospital, including a range of drug therapy 
options for the dying [6 – 8], international consensus 
on palliative end-of-life (EOL) drug treatment for 
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 Material and methods 
 Study population 
 NHs in Norway accommodate around 41 000 beds, 
corresponding to 18% of the general population 
80 years and older. All NHs provide EOL care, but 
only 42 institutions have specialized palliative care 
units. Most NH physicians in Norway are part-time 
engaged general practitioners [1]. The study popula-
tion comprised all patients in three urban NHs in 
Norway admitted from January 2008 and deceased 
before February 2013. The institutions were selected 
on the basis of using an electronic patient record 
system optimized for data extraction [10]. 
 Data collection 
 We collected routinely registered data from the 
patients ’ fi nal NH stay: demographic data (age, 
gender, date of NH admission and death, long- or 
short-term stay); diagnoses (ICD-10) [11]; medica-
tions (generic name, Anatomical Therapeutic Chem-
ical (ATC) code [12], drug formulation, regular or 
as-needed schedule, indication, dates of initiation, 
alteration, or discontinuation). An external IT con-
sultant extracted the data, and replaced ID-numbers 
with a running number, the key to which remained 
undisclosed to the research group. 
 Drug therapy 
 We defi ned palliative EOL drug therapy in NHs on 
the basis of indication, drug, and formulation; (1) 
any drug prescription with an explicit EOL care 
indication key word was included: palliative, termi-
nal, death, death rattle, Liverpool Care Pathway, or 
EOL; (2) we also included prescriptions of specifi -
cally recommended  injectable palliative EOL drugs 
for use in NHs [2,5], regardless of missing EOL key 
words in the indication text (Table I).  “ Curative/
preventive drug therapy ” , in contrast, was defi ned as 
medication for regular use without an explicit EOL 
care indication. 
 Statistical analysis 
 User rates were established for drugs according to 
the above categories. We explored predictors of pal-
liative EOL drug therapy by a chi-squared test, and 
subsequently by binary logistic regression analysis; 
dependent variable: palliative EOL drug therapy; 
independent variables: age, gender, length of stay, 
nursing home, diagnosis of cancer. All variables but 
age were analysed as categorical. Signifi cance was 
determined at a level of 5%. IBM SPSS Statistics 20 
(SPSS Inc., Chicago, Ill., USA) was used for statistical 
analyses. 
 Results 
 Patient characteristics 
 The study population comprised 524 deceased 
patients. Median (range) age at death was 86 
(19 – 104) years, 59.4% were women, 68.1% in long-
term care. The most common registered diagnoses 
were dementia (36.8% of the patients), congestive 
heart failure (29.6%), and cancer (23.7%) (Table II). 
 The three NH populations did not differ with 
regard to gender or number of diagnoses. Compared 
with the other NHs, more patients at NH C were 
86 years and older, or had a diagnosis of infection or 
cancer, p    0.01. Patients at NH A had longer stays 
 End-of-life care guidelines are centred on 
cancer patients, while nursing home patients 
die from various illnesses. 
 This study shows that palliative drugs were  •
commonly prescribed for nursing home 
patients during the last days of life. 
 A diagnosis of cancer and length of stay were  •
associated with palliative drug therapy. 
 Most initiations of palliative drugs, and most  •
withdrawals of curative/preventive drug 
therapy, occurred on the day of death. 
 Table I. Injectable drugs recommended for palliative treatment for the dying in NHs in 
Norway [2,5], by proportion (%) of users on the day of death. 
Drug name ATC code Common EOL use Proportion (%) of patients
Morphine N02AA01 Pain or dyspnoea 71.4
Glycopyrronium A03AB02 Death rattle 46.9
Scopolamine N05CM05 Death rattle 25.8
Morphine-scopolamine N02AG01 Pain or dyspnoea and death rattle 12.2
Midazolam N05CD08 Anxiety, agitation 55.0
Diazepam N05BA01 Anxiety, agitation 1.0
Haloperidol N05AD01 Nausea and terminal delirium 46.9
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(p    0.01), as the EPR data were collected from was 
used only in the long-term ward. 
 Patients with cancer more frequently died within 
two weeks of admission than patients without cancer 
(41.1% vs. 20.5%, p    0.01). Patients with dementia 
more frequently died after stays of longer than 
16 months compared with patients without this diag-
nosis (40.4% vs. 16.0%, p    0.01). 
 Drug use on the day of death 
 On the day of death, 99.4% of the study population 
were on drug therapy. The most common regular and 
as-needed drugs are shown in Table III. 
 Of the 4736 standing prescriptions (regular and 
as-needed drugs) on the day of death, palliative 
EOL drugs comprised 1306 (27.6%) and curative/
preventive drugs 2419 (51.1%), while 1011 (21.3%) 
prescriptions were not classifi ed in either category. 
Indication was documented for 99.6% of all drugs 
on the day of death. 
 Altogether 50.2% of patients were prescribed any 
drug with a specifi ed EOL care indication. The most 
common palliative EOL drugs were morphine 
(71.4% of patients), midazolam (55.0%), glycopyr-
ronium (46.9%), and haloperidol (46.9%) (see 
Table I). Palliative EOL drugs were prescribed to 
74.2% of the study population, either alone (26.9%) 
or concomitantly with curative/preventive drugs 
(47.3%). Curative/preventive drugs were prescribed 
to 72.5% of patients (alone 25.2%). Some 95.7% of 
palliative EOL drugs were prescribed as needed. 
Patients had standing prescriptions of median (25th –
 75th percentile) three (zero – eight) palliative EOL 
drugs and three (zero – four) curative/preventive 
drugs on the date of death. There was a median 
period of two (zero – seven) days from prescription to 
death for palliative EOL drugs. 
 Having prescriptions of palliative EOL drugs at 
death was associated with length of stay    16 months 
(AOR 2.10, 95% CI 1.13 – 3.95), cancer (2.12, 1.19 –
 3.76), age (1.03, 1.005 – 1.05), and being at NH B 
(3.53, 1.99 – 6.25) or NH C (4.20, 2.36 – 7.48) 
(Table IV). 
 Figure 1 shows that the proportion of patients for 
whom at least one palliative EOL drug was initiated, 
or at least one curative/preventive drug was discon-
tinued, increased in the last week before death and 
peaked on the day of death. 
 Table II. Patient characteristics (n    524). 
Median (range) age at death, years 86 (19 – 104)
Women, % 59.4
Median (range) length of stay, days 103 (0 – 1765)
Long-term care, % 68.1
Diagnoses:
Dementia, % 36.8
Congestive heart failure, % 29.6
Cancer, % 23.7
Chronic pulmonary disease, % 18.5
Infections, % 20.0
Hip fracture, % 9.7
 Table III. Most common drugs on the date of death (% of patients). 
ATC-code
Regular drugs
Drug subgroup
Proportion (%) 
of patients ATC-code
As-needed drugs
Drug subgroup
Proportion (%) 
of patients
A06A Laxatives 32.6 N02A Opioid analgesics 82.6
N02A Opioid analgesics 32.4 N05C Hypnotics 70.4
N02B Non-opioid analgesics and 
antipyretics
28.2 N05A Antipsychotics 51.1
C03C High-ceiling diuretics 26.7 N05B Anxiolytics 30.9
B01A Antithrombotic agents 24.0 N02B Non-opioid analgesics and antipyretics 26.0
N06A Antidepressants 19.1 A03A Drugs for functional gastrointestinal 
disorders 1 
24.6
C07A Beta-blocking agents 17.6 C03C High-ceiling diuretics 16.8
A02B Drugs for peptic ulcer and 
gastro-oesophageal refl ux 
disease
15.1 A03F Metoclopramide 13.4
B03B Vitamin B12 and folic acid 14.3 A06A Laxatives 13.0
N05C Hypnotics 13.5 C01D Vasodilators used in cardiac diseases 11.1
N05A Antipsychotics 11.5 R03A Adrenergic inhalants 6.3
N05B Anxiolytics 11.1 A10A Insulins and analogues 5.2
C09A ACE inhibitors, plain 8.6 B05B i.v. solutions 4.8
H02A Corticosteroids for systemic 
use, plain
8.4 R05C Expectorants, excl. combinations with 
cough suppressants
4.6
R03A Adrenergic inhalants 8.4 R03B Other drugs for obstructive airways 
disease, inhalants
4.4
 Note:  1 Glycopyrronium represented 84.8% of prescriptions in this category. 
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 Discussion 
 Our study shows that palliative EOL drugs were 
commonly prescribed for NH patients during the last 
days of life. NH, a diagnosis of cancer, and long stay 
were associated with palliative EOL drug therapy. 
Most initiations of palliative EOL drugs, and most 
withdrawals of curative/preventive drug therapy, 
occurred on the day of death. 
 Strengths and weaknesses 
 The study population comprised patients from all 
types of wards, and although the diagnostic data are 
not validated this broad diversity is expected to refl ect 
NH populations in general. 
 With the exception of short-term care patients 
from NH A, all patients admitted and deceased in 
three NHs during the fi ve-year study period were 
included, limiting selection bias. Only three institu-
tions participated in the study, limiting statistical 
power and to some extent generalizability. 
 A complete set of medication data for all patients 
was collected. The electronic patient record did not 
include information on whether prescribed medica-
tion was actually taken, leading to possible overesti-
mation of drug use. Prescribed medication, on the 
 Table IV. Associations between palliative EOL drug therapy and patient characteristics. 
Proportion of patients 
(%) prescribed 
palliative drugs Chi-square, p AOR 95% CI
Nursing home:
A 52.7    0.01 1 Ref
B 78.7 3.53 1.91 – 6.00
C 80.4 4.20 2.26 – 7.08
Length of stay (quartiles):
   2 weeks 81.2 0.01 1.86 0.97 – 3.25
2 weeks – 3 months 65.1 1 Ref
3 – 16 months 71.8 1.70 0.97 – 3.17
   16 months 78.6 2.10 1.13 – 3.95
Gender:
Women 75.8 0.31 1 Ref
Men 71.8 0.98 0.60 – 1.44
Age:
86  77.4 0.06 1.03 1.005 – 1.05
   86 70.0
No. of diagnoses:
  6 76.6 0.21 Variable not included
   6 71.7
Cancer:
No 71.5 0.01 1 Ref
Yes 83.1 2.12 1.30 – 4.13
Dementia:
No 72.2 0.16 1 Ref
Yes 77.7 1.43 0.88 – 2.25
Infections:
No 75.4 0.22 Variable not included
Yes 69.5
Chronic pulmonary disease:
No 75.2 0.30 Variable not included
Yes 70.1
Heart failure:
No 73.4 0.52 Variable not included
Yes 76.1
Hip fracture:
No 74.6 0.53 Variable not included
Yes 70.6
 Notes: Logistic regression model: chi-squared (8, 524)    58.41, p    0.001, Cox  & Snell R2    0.11, 
74.4% correctly classifi ed. The logistic regression was performed as a block analysis, each variable being 
adjusted by the effects of the others. Association strength is given as adjusted odds ratios (AORs), with 
95% confi dence intervals (CI). Only variables with a p    0.20 in the chi-squared test were included in 
the regression analysis, with the exception of gender which was included on the basis of being a common 
confounder. In the regression model, age was analysed as a continuous variable, all other included 
variables as categorical. Ref    reference value. 
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  End-of-life drug treatment in nursing homes  191
other hand, may refl ect the doctor ’ s treatment deci-
sions more appropriately than given medication. This 
point is particularly important for palliative drugs, 
which comprised almost exclusively as-needed drug 
prescriptions. 
 Use of indication text secured a comprehensive 
defi nition of palliative EOL drugs, while inclusion of 
specifi cally recommended palliative EOL drugs 
ensured that these prescriptions were not missed 
regardless of missing EOL key words in the indica-
tion text. Restricting the latter to injectables, we 
excluded prescriptions less specifi c to the dying 
patient, such as opioid tablets, oral suspensions, and 
patches. Injectable antipsychotics and benzodia-
zepines may on occasion be used to treat neuropsy-
chiatric symptoms in dementia. A median of two 
days from prescription to death makes it less likely, 
though, that these prescriptions were issued for their 
non-palliative indications. Although anticholinergics 
have other indications, in injectable form, glycopyr-
ronium and scopolamine are seldom used for non-
palliative purposes in NHs. 
 Comparison with other studies 
 There are few other studies reporting on drug ther-
apy at the EOL in the general NH population, and 
with considerably smaller sample sizes. Decreased 
overall treatment intensity has been found in patients 
perceived as dying, across NH, hospital, and general 
practice settings in the Netherlands [13]. Patients 
with dementia dying in American NHs were pre-
scribed unchanged total numbers of drugs, palliative 
medications replacing other medications [9]. 
 Our study adds to previous knowledge showing 
that NH patients with the longest duration of stay, 
or a diagnosis of cancer, were more likely to receive 
palliative EOL drugs on the day of death than those 
without these characteristics. More than 80% of long-
term care patients have dementia [14], interfering 
with the communication of suffering, analgesia, and 
EOL care [15 – 17]. Accurate survival prediction for 
patients with advanced dementia is diffi cult, and 
may hinder palliative care [18]. Longer NH stays may 
nevertheless allow time for advance care planning 
and staff familiarity with the patient, thus facilitating 
palliation, and perhaps explaining the association 
found with the longest stays. Patients with cancer 
often have expected deaths with a typically rapid 
functional decline, and are at the centre of palliative 
guidelines [7,19]. Palliative drug therapy for this 
group was therefore expected. A diagnosis of demen-
tia, heart failure, chronic pulmonary disease, infec-
tion, or hip fracture was not associated with initiation 
of palliative drugs. This may indicate death coming 
unexpectedly. For respiratory distress in chronic pul-
monary disease there may also be a reservation among 
physicians to prescribe morphine and benzodia-
zepines, as they inhibit respiration. 
 An evidence base for EOL care in non-malignant 
conditions, which are prevalent in the general NH 
population, is scarce [20]. We found a high treatment 
rate with palliative drugs (73.9% overall, 71.9% for 
morphine), in line with 77% of NH patients with 
advanced dementia in the Netherlands receiving opi-
oids. Despite extensive prescribing, the Dutch study 
found that symptoms of pain, shortness of breath, 
and agitation were prevalent, suggesting that a pre-
scribed drug is no guarantee of satisfactory symptom 
control [21]. For this, factors such as close symptom 
assessment as well as appropriate drug dosage and 
administration are required. 
 Palliative drug therapy increased and curative/
preventive drug treatment decreased in the last week 
of life, most changes taking place on the day of death. 
A recent study in long-term care facilities in Canada 
found that care only changed substantially to pallia-
tive in nature during the last hours or days of life, 
calling for earlier awareness of impending death [22]. 
Initiation of palliative drugs is not to be expected for 
all dying patients, nor does it depend only on staff 
competence. Less palliative drug therapy could also 
come from less need for it, by having a shorter ter-
minal phase, or less burdensome symptoms. Little is 
known about the identifi cation and duration of the 
dying phase in NH patients and for how many it lasts 
long enough to allow for pharmacological response. 
Distinct death trajectories have been described for 
patients with different diseases [23], and timing of 
palliative care for patients with non-malignant diag-
noses has been shown to be particularly challenging 
[24]. Yet, relatively accurate prediction of survival for 
these patients in NHs has been shown to be feasible, 
though only in the last seven days of life [25]. 
 NH A had a lower proportion of patients pre-
scribed palliative medications at death. Differences 
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 Figure 1. Proportion of patients (%) for whom at least one 
palliative EOL drug was initiated, or at least one curative/preventive 
drug was discontinued during the last 14 days of life. 
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192 K. Jansen et al. 
in prescribing culture between doctors may be one 
explanation. For the present study we did not collect 
this variable. 
 Meaning of the study 
 Palliative drug prescriptions and drug therapy 
changes are common for NH patients on the last day 
of life. Extensive curative/preventive drug therapy 
and comprehensive changes in drug treatment on the 
day of death may both point to the known prognos-
tication diffi culties in the multimorbidity character-
izing NH populations. Improvements of EOL care in 
NHs must address prognostication and an early 
response to palliative needs. 
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